We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microfluidic Chip Captures Live Tumor Cells from Blood

By LabMedica International staff writers
Posted on 28 Aug 2013
A neoteric microfluidic chip has been developed that can quickly and efficiently segregate and capture live circulating tumor cells (CTCs) from a patient's blood.

The chip has potential applications for cancer screenings and treatment assessments as CTCs circulating within a patient's bloodstream can carry cancer from a primary tumor site to distant sites of the body, spreading the disease. More...


A team of scientists at Peking University (Beijing, China) developed the system that captures more than 90% of the CTCs, which makes it highly efficient. Overall processing time has also been shortened, due in part to a step in which red blood cells are selectively lysed, or broken apart. Lysing the red blood cells diminishes the tendency of blood to clog the system, a common problem that slows processing time in similar CTC filtering devices.

The microfluidic system consists of the chip itself, tubing, fluid connectors, syringes, and syringe pumps. Tubes and fluid connectors are used to connect the syringes, and fluidic ports punched into the microfluidic chip. The ability to count live, individual CTCs in the bloodstream can help doctors determine the severity of a cancer, since CTC density in the blood is linked to the progression of the disease and patients' likelihood of survival. The novel method could also improve "liquid biopsy" techniques, in which a small amount of blood is drawn as an alternative to conventional tissue biopsies of primary or metastatic tumors.

Ray P.S. Han, PhD, a professor and lead author, said, “Because our chip is able to capture viable CTCs, it creates opportunities for the development of new and efficient cancer biomarkers. It also gives us a chance of the grandest dream of all: a technology capable of directly removing CTCs from the human bloodstream, a form of CTC dialysis." The study was published online on June 6, 2013, in the journal Biomicrofluidics.

Related Links:
Peking University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Automated Immunoassay Analyzer
SuperFlex™
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.